AR and prostate cancer: This Study demonstrated that targeting PCBP1-AS1 increases the sensitivity of prostate cancer cells to Enzalutamide by reducing the binding of USP22 to AR-V7 or AR and decreasing the stability of the complex, providing new ideas for the clinical treatment of drug-resistant patients with CRPC.